ID: ALA3085357

Max Phase: Preclinical

Molecular Formula: C21H30BrN3O3

Molecular Weight: 452.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  C/C(Br)=C\CC/C(C)=C/CC(C)(C)/C=C/C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O

Standard InChI:  InChI=1S/C21H30BrN3O3/c1-15(6-5-7-16(2)22)8-10-21(3,4)11-9-19(26)25-18(20(27)28)12-17-13-23-14-24-17/h7-9,11,13-14,18H,5-6,10,12H2,1-4H3,(H,23,24)(H,25,26)(H,27,28)/b11-9+,15-8+,16-7+/t18-/m0/s1

Standard InChI Key:  NCMICRLHSYYCPS-ZXDZJFMASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 452.39

Molecular Weight (Monoisotopic): 451.1471

AlogP: 4.52

#Rotatable Bonds: 11

Polar Surface Area: 95.08

Molecular Species: ACID

HBA: 3

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.87

CX Basic pKa: 6.75

CX LogP: 2.64

CX LogD: 1.89

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.34

Np Likeness Score: 0.70

References

1. Kitayama T, Iwabuchi R, Minagawa S, Sawada S, Okumura R, Hoshino K, Cappiello J, Utsumi R..  (2007)  Synthesis of a novel inhibitor against MRSA and VRE: preparation from zerumbone ring opening material showing histidine-kinase inhibition.,  17  (4): [PMID:17157007] [10.1016/j.bmcl.2006.11.015]

Source

Source(1):

• Scientific Literature